+357 96 030922
info@marketpublishers.com

Global Non-Opioid Pain Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032

https://marketpublishers.com/r/GB845ED2F715EN.html
Date: September 2026
Pages: 157
Price: US$ 3,480.00 (Single User License)
ID: GB845ED2F715EN

Abstracts

According to our (Global Info Research) latest study, the global Non-Opioid Pain Drug market size was valued at US$ 43374 million in 2025 and is forecast to a readjusted size of US$ 58915 million by 2032 with a CAGR of 4.4% during review period.

Non-Opioid Pain Drug refers to pharmaceutical products that provide analgesic effects without relying on opioid receptor agonism as their primary pain-relief mechanism. The market covers a broad therapeutic spectrum ranging from established systemic analgesics to newer mechanism-specific and site-directed therapies, with major product categories including acetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors, sodium channel pain signal inhibitors, local anesthetic analgesics, capsaicin-based analgesics, anticonvulsant analgesics, antidepressant analgesics and other non-opioid therapies. Products are commercialized as single-agent or combination drugs, across prescription and over-the-counter channels, and in oral, injectable, topical, transdermal and other formulations. The principal clinical applications include postoperative pain, musculoskeletal pain, arthritis pain, neuropathic pain, headache and migraine, dental pain, back pain, menstrual pain, injury and trauma pain, and selected cancer-related pain settings. The research focus therefore spans both high-volume routine pain management and differentiated prescription therapies designed for more targeted, prolonged or opioid-sparing analgesia.

Key Findings

The average gross profit margin of this product is 45%

+357 96 030922
info@marketpublishers.com

NSAIDs and acetaminophen remain the broadest treatment foundation across pain care

Prescription innovation increasingly targets peripheral pain signaling without opioid receptor activation

Postoperative pain is a strategic field for long acting local analgesia

Oral drugs anchor routine use while topical formats widen treatment access

Competition spans consumer health specialty pharma and broad generic portfolios

Market Trends

The Non-Opioid Pain Drug market is moving from a structure dominated primarily by conventional systemic analgesics toward a more diversified treatment model combining established drugs, mechanism-targeted therapies, localized delivery and multimodal pain management. NSAIDs and acetaminophen continue to underpin routine acute and musculoskeletal pain treatment, while innovation is increasingly focused on improving analgesic selectivity, duration of action and site specificity. The U.S. FDA approval of suzetrigine in 2025 introduced a new class of oral non-opioid analgesia targeting peripheral sodium-channel-mediated pain signaling, illustrating the industry's growing interest in treating pain before signals reach central pathways. At the same time, prolonged local anesthetic formulations and dual-mechanism perioperative therapies are broadening the role of non-opioid drugs in postoperative pain management. Consumer pain-care products are also evolving through differentiated release profiles, topical formulations and fixed-dose combinations. The long-term direction of the market is therefore shifting from simply replacing opioids with conventional analgesics toward matching different pain mechanisms, treatment durations and clinical scenarios with more specialized non-opioid options.

Market Dynamics

Drivers

+357 96 030922
info@marketpublishers.com

Demand for Non-Opioid Pain Drug products is supported by the persistent clinical burden of acute and chronic pain and by efforts to minimize unnecessary opioid exposure where effective alternatives are available. Non-opioid therapies already play an established role in common acute pain conditions, including musculoskeletal injuries, back pain and minor procedural pain, while acetaminophen, oral and topical NSAIDs and other non-opioid medicines remain widely integrated into routine treatment pathways. Clinical practice is increasingly emphasizing treatment selection according to pain type, expected duration, patient risk factors and functional goals rather than relying on a single analgesic class. This creates a broad demand base covering both consumer self-care products and prescription therapies. Perioperative care represents an additional driver as hospitals and clinicians increasingly use multimodal analgesic strategies combining systemic medicines with long-acting or site-specific local therapies to improve pain control while reducing reliance on opioid rescue medication.

Restraints

The principal limitation of the Non-Opioid Pain Drug market is that non-opioid does not mean clinically unrestricted. Established drug classes have well-defined dosing, contraindication and tolerability considerations that limit their use in particular patient populations. NSAIDs, for example, are associated with gastrointestinal and cardiovascular risks that become particularly relevant in older patients, patients with underlying disease and prolonged treatment settings. Other therapeutic classes similarly require patient-specific assessment and may not provide adequate analgesia for every pain severity or mechanism. At the commercial level, many traditional non-opioid analgesics are mature and highly genericized, creating strong price competition and limiting differentiation for standard formulations. Conversely, newer proprietary therapies may face higher treatment costs, reimbursement scrutiny and formulary barriers. The market consequently operates between two pressures: commoditization in established drug classes and the need for newer therapies to demonstrate sufficient clinical and economic value to justify premium positioning.

Opportunities

The most important opportunity lies in expanding the therapeutic space between conventional first-line analgesics and opioid therapy. Mechanism-specific oral medicines, prolonged local anesthetics, topical and transdermal therapies and rational combination products provide multiple routes for companies to address this gap. Acute moderate-to-severe pain is becoming particularly important because successful non-

+357 96 030922
info@marketpublishers.com

opioid products can potentially participate in treatment settings historically associated with substantial opioid use. The emergence of peripheral sodium channel pain signal inhibition demonstrates the potential for fundamentally new analgesic mechanisms, while extended-duration local therapies create opportunities in surgery and procedure-related pain. Additional opportunities exist in neuropathic pain, musculoskeletal disorders and targeted topical treatment, where patient heterogeneity favors differentiated therapeutic approaches. Combination products also offer potential to improve onset, duration or multimodal efficacy without relying on opioid components, supporting continued product reformulation and lifecycle innovation across both prescription and consumer-health markets.

Challenges

A central challenge for the Non-Opioid Pain Drug industry is translating pharmacological innovation into clinically meaningful advantages across highly heterogeneous pain conditions. Pain intensity is subjective, treatment response differs substantially among patients, and acute, inflammatory, neuropathic and postoperative pain involve different biological mechanisms. A therapy that performs well in one setting therefore cannot automatically establish broad value across the entire pain market. New prescription products must demonstrate not only statistically significant pain reduction but also clinically relevant improvements in duration, tolerability, functional recovery, opioid-sparing potential or ease of use. Companies must then secure reimbursement, hospital formulary access, physician adoption and patient acceptance while competing against inexpensive generic analgesics. Long development timelines and demanding clinical endpoints further increase commercialization risk. As the number of non-opioid approaches expands, differentiation will increasingly depend on clearly identifying the pain population, treatment setting and clinical value proposition in which each therapy provides a meaningful advantage.

Industry Chain Analysis

The upstream portion of the Non-Opioid Pain Drug industry consists primarily of active pharmaceutical ingredients, pharmaceutical intermediates, excipients and specialized formulation or drug-delivery materials. Conventional oral analgesics rely heavily on mature API manufacturing and large-scale solid-dose production, making manufacturing efficiency, quality control and supply security important competitive factors. More differentiated products introduce additional technical requirements, including sustained-

+357 96 030922
info@marketpublishers.com

release technologies, liposomal delivery systems, transdermal matrices, topical penetration systems and specialized injectable formulations. These technologies increase formulation complexity and can shift value creation away from the active ingredient alone toward proprietary delivery platforms, manufacturing know-how and intellectual property.

The midstream encompasses formulation development, clinical development, regulatory approval, commercial manufacturing, brand management and lifecycle management. Downstream channels differ significantly by product positioning: over-the-counter analgesics depend heavily on pharmacies, retail and consumer-health distribution, while prescription products rely more strongly on hospitals, physicians, specialty pharmacy and institutional formularies. In postoperative applications, adoption is closely linked to surgical protocols and hospital pain-management pathways. The value chain is therefore bifurcated. Mature generic products derive competitive advantage from manufacturing scale, procurement efficiency and channel coverage, whereas innovative non-opioid therapies capture value through differentiated mechanisms, longer duration of action, targeted delivery, clinical evidence and intellectual-property protection.

Segment Insights

From a Type perspective, acetaminophen/paracetamol and NSAIDs represent the broadest foundation of the Non-Opioid Pain Drug market because of their established role across common acute, inflammatory, dental, musculoskeletal and self-treated pain. Selective COX-2 inhibitors occupy a more differentiated anti-inflammatory position, while local anesthetic analgesics have particular relevance in procedural and postoperative settings. Sodium channel pain signal inhibitors represent an emerging mechanism-oriented segment following the introduction of a first-in-class therapy for moderate-to-severe acute pain. Capsaicin-based products, anticonvulsant analgesics and antidepressant analgesics address more specialized pain mechanisms, particularly neuropathic and chronic pain conditions. The market is consequently becoming more segmented by pain biology rather than being defined only by analgesic strength.

Across Class, Group and Sort, single-agent drugs continue to provide the core treatment base, while combination products offer opportunities for complementary mechanisms and differentiated duration or onset of action. Prescription products are particularly important where pain severity, comorbidity or specialized delivery requires physician supervision, whereas OTC medicines remain central to everyday pain self-management. Oral formulations provide the widest routine-use platform, but injectable,

+357 96 030922
info@marketpublishers.com

topical and transdermal products allow treatment to become more site-specific and can address patients or clinical scenarios where systemic exposure is less desirable. The development of prolonged local analgesia and increasingly differentiated topical pain products suggests that formulation technology is becoming an important source of competitive separation alongside active pharmaceutical innovation.

Downstream Market Opportunities

Downstream demand for Non-Opioid Pain Drug products spans everyday self-treated pain and highly managed clinical pain pathways. Musculoskeletal pain, arthritis, back pain, headache and migraine, dental pain and menstrual pain provide recurring demand for accessible oral and topical products, while neuropathic pain requires more mechanism-specific pharmacotherapy. Postoperative pain represents one of the most strategically important opportunities because treatment decisions occur within structured hospital and surgical protocols where duration of analgesia, recovery quality and opioid-sparing potential can materially influence product selection. Injury and trauma pain also support short-term acute treatment demand, while selected cancer-related pain settings create opportunities for non-opioid medicines as components of multimodal therapy. The major commercial opportunity is therefore not a single application, but the progressive segmentation of pain management according to etiology, severity, duration and treatment setting.

Regional Insights

North America is an important innovation and commercialization market for Non-Opioid Pain Drug products, particularly for novel prescription mechanisms and perioperative pain-management therapies. Recent regulatory progress in peripheral sodium channel inhibition and continued development of extended-duration local analgesics demonstrate active efforts to broaden non-opioid treatment options in acute and postoperative pain. The region also has a mature consumer-health market supported by established OTC analgesic brands. Europe similarly represents a mature market, with significant use of both prescription and OTC pain medicines and opportunities centered on formulation differentiation, localized pain treatment and improved patient selection.

Asia-Pacific combines a large base of conventional analgesic use with expanding demand for branded OTC products, prescription pain management and differentiated formulations. Japan has a well-developed topical and transdermal pain-treatment

+357 96 030922
info@marketpublishers.com

tradition, while China combines large-scale generic pharmaceutical manufacturing with increasing development of innovative and higher-value prescription therapies. Across emerging markets, affordability and broad distribution remain critical, meaning established oral drugs are likely to retain substantial importance even as more specialized products expand. Regional competition will therefore remain structurally different: innovation and premium prescription therapies are more prominent in developed markets, while manufacturing economics, accessibility and channel penetration remain especially influential in price-sensitive markets.

Competitive Landscape Analysis

The competitive landscape is structurally diversified rather than dominated by one type of pharmaceutical company. Within the confirmed company set, Kenvue, Haleon and Bayer participate strongly through established consumer pain-care portfolios, while Vertex Pharmaceuticals Incorporated, Pfizer Inc., Pacira BioSciences, Inc., Heron Therapeutics, Inc., Scilex Holding Company and Grünenthal GmbH represent prescription or specialty-pharma approaches to differentiated pain management. Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Healthcare Co., Ltd. and AFT Pharmaceuticals Limited add regional and formulation-focused positions, while Viatris Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. participate through broad pharmaceutical portfolios and large-scale manufacturing capabilities; Jiangsu Hengrui Pharmaceuticals Co., Ltd. represents the confirmed Chinese participant in the research scope. Competition therefore occurs across several dimensions simultaneously: consumer brand recognition, manufacturing scale, prescription access, formulation technology, proprietary mechanisms, clinical evidence and distribution reach. Recent progress in selective peripheral pain signaling and prolonged local analgesia indicates that future competitive differentiation is likely to rely increasingly on mechanism specificity and demonstrable clinical value rather than simple expansion of conventional analgesic portfolios.

Report Scope

This report is a detailed and comprehensive analysis for global Non-Opioid Pain Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that

+357 96 030922
info@marketpublishers.com

contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Non-Opioid Pain Drug market size and forecasts, in consumption value ($ Million), 2021-2032

Global Non-Opioid Pain Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032

Global Non-Opioid Pain Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032

Global Non-Opioid Pain Drug market shares of main players, in revenue ($ Million), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Non-Opioid Pain Drug

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Non-Opioid Pain Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Vertex Pharmaceuticals, Kenvue, Haleon, Bayer, Pfizer, Pacira BioSciences, Heron Therapeutics, Scilex Holding, Grünenthal, Hisamitsu Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities,

+357 96 030922
info@marketpublishers.com

new product launches or approvals.

Non-Opioid Pain Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Market segment by Type

Acetaminophen/Paracetamol

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Selective COX-2 Inhibitors

Sodium Channel Pain Signal Inhibitors

Local Anesthetic Analgesics

Other

Market segment by Drug Ingredients

Single-Agent Drugs

Combination Drugs

Market segment by Route of Administration

Oral Drugs

Injectable Drugs

+357 96 030922
info@marketpublishers.com

Topical Drugs

Market segment by Application

Postoperative Pain

Musculoskeletal Pain

Arthritis Pain

Neuropathic Pain

Headache and Migraine

Other

Market segment by players, this report covers

Vertex Pharmaceuticals

Kenvue

Haleon

Bayer

Pfizer

Pacira BioSciences

Heron Therapeutics

Scilex Holding

Grünenthal

+357 96 030922
info@marketpublishers.com

Hisamitsu Pharmaceutical

Daiichi Sankyo

AFT Pharmaceuticals

Viatris

Teva Pharmaceutical

Dr. Reddy's

Sun Pharmaceutical

Jiangsu Hengrui

Johnson & Johnson

Hubei Hendi Pharmaceutical

CSPC Pharmaceutical Group

Simcere Pharmaceutical

Qilu Pharmaceutical

Yichang Humanwell Pharmaceutical

Tongfang Pharma

Fresenius

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

+357 96 030922
info@marketpublishers.com

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Chapter Outline

Chapter 1, to describe Non-Opioid Pain Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Non-Opioid Pain Drug, with revenue, gross margin, and global market share of Non-Opioid Pain Drug from 2021 to 2026.

Chapter 3, the Non-Opioid Pain Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Non-Opioid Pain Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Non-Opioid Pain Drug.

Chapter 13, to describe Non-Opioid Pain Drug research findings and conclusion.

+357 96 030922
info@marketpublishers.com

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Non-Opioid Pain Drug by Type
  1.3.1 Overview: Global Non-Opioid Pain Drug Market Size by Type: 2021 Versus 2025 Versus 2032
  1.3.2 Global Non-Opioid Pain Drug Consumption Value Market Share by Type in 2025
  1.3.3 Acetaminophen/Paracetamol
  1.3.4 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  1.3.5 Selective COX-2 Inhibitors
  1.3.6 Sodium Channel Pain Signal Inhibitors
  1.3.7 Local Anesthetic Analgesics
  1.3.8 Other
1.4 Classification of Non-Opioid Pain Drug by Drug Ingredients
  1.4.1 Overview: Global Non-Opioid Pain Drug Market Size by Drug Ingredients: 2021 Versus 2025 Versus 2032
  1.4.2 Global Non-Opioid Pain Drug Consumption Value Market Share by Drug Ingredients in 2025
  1.4.3 Single-Agent Drugs
  1.4.4 Combination Drugs
1.5 Classification of Non-Opioid Pain Drug by Route of Administration
  1.5.1 Overview: Global Non-Opioid Pain Drug Market Size by Route of Administration: 2021 Versus 2025 Versus 2032
  1.5.2 Global Non-Opioid Pain Drug Consumption Value Market Share by Route of Administration in 2025
  1.5.3 Oral Drugs
  1.5.4 Injectable Drugs
  1.5.5 Topical Drugs
1.6 Global Non-Opioid Pain Drug Market by Application
  1.6.1 Overview: Global Non-Opioid Pain Drug Market Size by Application: 2021 Versus 2025 Versus 2032
  1.6.2 Postoperative Pain
  1.6.3 Musculoskeletal Pain
  1.6.4 Arthritis Pain
  1.6.5 Neuropathic Pain
  1.6.6 Headache and Migraine

+357 96 030922
info@marketpublishers.com

1.6.7 Other
1.7 Global Non-Opioid Pain Drug Market Size & Forecast
1.8 Global Non-Opioid Pain Drug Market Size and Forecast by Region
1.8.1 Global Non-Opioid Pain Drug Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Non-Opioid Pain Drug Market Size by Region, (2021-2032)
1.8.3 North America Non-Opioid Pain Drug Market Size and Prospect (2021-2032)
1.8.4 Europe Non-Opioid Pain Drug Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Non-Opioid Pain Drug Market Size and Prospect (2021-2032)
1.8.6 South America Non-Opioid Pain Drug Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Non-Opioid Pain Drug Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

2.1 Vertex Pharmaceuticals
2.1.1 Vertex Pharmaceuticals Details
2.1.2 Vertex Pharmaceuticals Major Business
2.1.3 Vertex Pharmaceuticals Non-Opioid Pain Drug Product and Solutions
2.1.4 Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Vertex Pharmaceuticals Recent Developments and Future Plans
2.2 Kenvue
2.2.1 Kenvue Details
2.2.2 Kenvue Major Business
2.2.3 Kenvue Non-Opioid Pain Drug Product and Solutions
2.2.4 Kenvue Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Kenvue Recent Developments and Future Plans
2.3 Haleon
2.3.1 Haleon Details
2.3.2 Haleon Major Business
2.3.3 Haleon Non-Opioid Pain Drug Product and Solutions
2.3.4 Haleon Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Haleon Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Non-Opioid Pain Drug Product and Solutions

+357 96 030922
info@marketpublishers.com

2.4.4 Bayer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Bayer Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Non-Opioid Pain Drug Product and Solutions
2.5.4 Pfizer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Pacira BioSciences
2.6.1 Pacira BioSciences Details
2.6.2 Pacira BioSciences Major Business
2.6.3 Pacira BioSciences Non-Opioid Pain Drug Product and Solutions
2.6.4 Pacira BioSciences Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Pacira BioSciences Recent Developments and Future Plans
2.7 Heron Therapeutics
2.7.1 Heron Therapeutics Details
2.7.2 Heron Therapeutics Major Business
2.7.3 Heron Therapeutics Non-Opioid Pain Drug Product and Solutions
2.7.4 Heron Therapeutics Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Heron Therapeutics Recent Developments and Future Plans
2.8 Scilex Holding
2.8.1 Scilex Holding Details
2.8.2 Scilex Holding Major Business
2.8.3 Scilex Holding Non-Opioid Pain Drug Product and Solutions
2.8.4 Scilex Holding Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Scilex Holding Recent Developments and Future Plans
2.9 Grünenthal
2.9.1 Grünenthal Details
2.9.2 Grünenthal Major Business
2.9.3 Grünenthal Non-Opioid Pain Drug Product and Solutions
2.9.4 Grünenthal Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Grünenthal Recent Developments and Future Plans
2.10 Hisamitsu Pharmaceutical

+357 96 030922
info@marketpublishers.com

2.10.1 Hisamitsu Pharmaceutical Details
2.10.2 Hisamitsu Pharmaceutical Major Business
2.10.3 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product and Solutions
2.10.4 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Hisamitsu Pharmaceutical Recent Developments and Future Plans
2.11 Daiichi Sankyo
2.11.1 Daiichi Sankyo Details
2.11.2 Daiichi Sankyo Major Business
2.11.3 Daiichi Sankyo Non-Opioid Pain Drug Product and Solutions
2.11.4 Daiichi Sankyo Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Daiichi Sankyo Recent Developments and Future Plans
2.12 AFT Pharmaceuticals
2.12.1 AFT Pharmaceuticals Details
2.12.2 AFT Pharmaceuticals Major Business
2.12.3 AFT Pharmaceuticals Non-Opioid Pain Drug Product and Solutions
2.12.4 AFT Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 AFT Pharmaceuticals Recent Developments and Future Plans
2.13 Viatris
2.13.1 Viatris Details
2.13.2 Viatris Major Business
2.13.3 Viatris Non-Opioid Pain Drug Product and Solutions
2.13.4 Viatris Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Viatris Recent Developments and Future Plans
2.14 Teva Pharmaceutical
2.14.1 Teva Pharmaceutical Details
2.14.2 Teva Pharmaceutical Major Business
2.14.3 Teva Pharmaceutical Non-Opioid Pain Drug Product and Solutions
2.14.4 Teva Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Teva Pharmaceutical Recent Developments and Future Plans
2.15 Dr. Reddy's
2.15.1 Dr. Reddy's Details
2.15.2 Dr. Reddy's Major Business
2.15.3 Dr. Reddy's Non-Opioid Pain Drug Product and Solutions
2.15.4 Dr. Reddy's Non-Opioid Pain Drug Revenue, Gross Margin and Market Share

+357 96 030922
info@marketpublishers.com

(2021-2026)
2.15.5 Dr. Reddy's Recent Developments and Future Plans
2.16 Sun Pharmaceutical
2.16.1 Sun Pharmaceutical Details
2.16.2 Sun Pharmaceutical Major Business
2.16.3 Sun Pharmaceutical Non-Opioid Pain Drug Product and Solutions
2.16.4 Sun Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Sun Pharmaceutical Recent Developments and Future Plans
2.17 Jiangsu Hengrui
2.17.1 Jiangsu Hengrui Details
2.17.2 Jiangsu Hengrui Major Business
2.17.3 Jiangsu Hengrui Non-Opioid Pain Drug Product and Solutions
2.17.4 Jiangsu Hengrui Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Jiangsu Hengrui Recent Developments and Future Plans
2.18 Johnson & Johnson
2.18.1 Johnson & Johnson Details
2.18.2 Johnson & Johnson Major Business
2.18.3 Johnson & Johnson Non-Opioid Pain Drug Product and Solutions
2.18.4 Johnson & Johnson Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Johnson & Johnson Recent Developments and Future Plans
2.19 Hubei Hendi Pharmaceutical
2.19.1 Hubei Hendi Pharmaceutical Details
2.19.2 Hubei Hendi Pharmaceutical Major Business
2.19.3 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product and Solutions
2.19.4 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Hubei Hendi Pharmaceutical Recent Developments and Future Plans
2.20 CSPC Pharmaceutical Group
2.20.1 CSPC Pharmaceutical Group Details
2.20.2 CSPC Pharmaceutical Group Major Business
2.20.3 CSPC Pharmaceutical Group Non-Opioid Pain Drug Product and Solutions
2.20.4 CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 CSPC Pharmaceutical Group Recent Developments and Future Plans
2.21 Simcere Pharmaceutical
2.21.1 Simcere Pharmaceutical Details

+357 96 030922
info@marketpublishers.com

2.21.2 Simcere Pharmaceutical Major Business
2.21.3 Simcere Pharmaceutical Non-Opioid Pain Drug Product and Solutions
2.21.4 Simcere Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.21.5 Simcere Pharmaceutical Recent Developments and Future Plans
2.22 Qilu Pharmaceutical
2.22.1 Qilu Pharmaceutical Details
2.22.2 Qilu Pharmaceutical Major Business
2.22.3 Qilu Pharmaceutical Non-Opioid Pain Drug Product and Solutions
2.22.4 Qilu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.22.5 Qilu Pharmaceutical Recent Developments and Future Plans
2.23 Yichang Humanwell Pharmaceutical
2.23.1 Yichang Humanwell Pharmaceutical Details
2.23.2 Yichang Humanwell Pharmaceutical Major Business
2.23.3 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product and Solutions
2.23.4 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.23.5 Yichang Humanwell Pharmaceutical Recent Developments and Future Plans
2.24 Tongfang Pharma
2.24.1 Tongfang Pharma Details
2.24.2 Tongfang Pharma Major Business
2.24.3 Tongfang Pharma Non-Opioid Pain Drug Product and Solutions
2.24.4 Tongfang Pharma Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.24.5 Tongfang Pharma Recent Developments and Future Plans
2.25 Fresenius
2.25.1 Fresenius Details
2.25.2 Fresenius Major Business
2.25.3 Fresenius Non-Opioid Pain Drug Product and Solutions
2.25.4 Fresenius Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
2.25.5 Fresenius Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Non-Opioid Pain Drug Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)

+357 96 030922
info@marketpublishers.com

3.2.1 Market Share of Non-Opioid Pain Drug by Company Revenue
3.2.2 Top 3 Non-Opioid Pain Drug Players Market Share in 2025
3.2.3 Top 6 Non-Opioid Pain Drug Players Market Share in 2025
3.3 Non-Opioid Pain Drug Market: Overall Company Footprint Analysis
3.3.1 Non-Opioid Pain Drug Market: Region Footprint
3.3.2 Non-Opioid Pain Drug Market: Company Product Type Footprint
3.3.3 Non-Opioid Pain Drug Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Non-Opioid Pain Drug Consumption Value and Market Share by Type (2021-2026)
4.2 Global Non-Opioid Pain Drug Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Non-Opioid Pain Drug Consumption Value Market Share by Application (2021-2026)
5.2 Global Non-Opioid Pain Drug Market Forecast by Application (2027-2032)

6 NORTH AMERICA

6.1 North America Non-Opioid Pain Drug Consumption Value by Type (2021-2032)
6.2 North America Non-Opioid Pain Drug Market Size by Application (2021-2032)
6.3 North America Non-Opioid Pain Drug Market Size by Country
6.3.1 North America Non-Opioid Pain Drug Consumption Value by Country (2021-2032)
6.3.2 United States Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
6.3.3 Canada Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
6.3.4 Mexico Non-Opioid Pain Drug Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe Non-Opioid Pain Drug Consumption Value by Type (2021-2032)
7.2 Europe Non-Opioid Pain Drug Consumption Value by Application (2021-2032)
7.3 Europe Non-Opioid Pain Drug Market Size by Country
7.3.1 Europe Non-Opioid Pain Drug Consumption Value by Country (2021-2032)

+357 96 030922
info@marketpublishers.com

7.3.2 Germany Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
7.3.3 France Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
7.3.5 Russia Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
7.3.6 Italy Non-Opioid Pain Drug Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific Non-Opioid Pain Drug Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Non-Opioid Pain Drug Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Non-Opioid Pain Drug Market Size by Region
8.3.1 Asia-Pacific Non-Opioid Pain Drug Consumption Value by Region (2021-2032)
8.3.2 China Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
8.3.3 Japan Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
8.3.4 South Korea Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
8.3.5 India Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
8.3.7 Australia Non-Opioid Pain Drug Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

9.1 South America Non-Opioid Pain Drug Consumption Value by Type (2021-2032)
9.2 South America Non-Opioid Pain Drug Consumption Value by Application (2021-2032)
9.3 South America Non-Opioid Pain Drug Market Size by Country
9.3.1 South America Non-Opioid Pain Drug Consumption Value by Country (2021-2032)
9.3.2 Brazil Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
9.3.3 Argentina Non-Opioid Pain Drug Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Non-Opioid Pain Drug Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Non-Opioid Pain Drug Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Non-Opioid Pain Drug Market Size by Country
10.3.1 Middle East & Africa Non-Opioid Pain Drug Consumption Value by Country (2021-2032)

+357 96 030922
info@marketpublishers.com

10.3.2 Turkey Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Non-Opioid Pain Drug Market Size and Forecast (2021-2032)
10.3.4 UAE Non-Opioid Pain Drug Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 Non-Opioid Pain Drug Market Drivers
11.2 Non-Opioid Pain Drug Market Restraints
11.3 Non-Opioid Pain Drug Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Non-Opioid Pain Drug Industry Chain
12.2 Non-Opioid Pain Drug Upstream Analysis
12.3 Non-Opioid Pain Drug Midstream Analysis
12.4 Non-Opioid Pain Drug Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Global Non-Opioid Pain Drug Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Non-Opioid Pain Drug Consumption Value by Drug Ingredients, (USD Million), 2021 & 2025 & 2032
Table 3. Global Non-Opioid Pain Drug Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 4. Global Non-Opioid Pain Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Non-Opioid Pain Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Non-Opioid Pain Drug Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Vertex Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 8. Vertex Pharmaceuticals Major Business
Table 9. Vertex Pharmaceuticals Non-Opioid Pain Drug Product and Solutions
Table 10. Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Vertex Pharmaceuticals Recent Developments and Future Plans
Table 12. Kenvue Company Information, Head Office, and Major Competitors
Table 13. Kenvue Major Business
Table 14. Kenvue Non-Opioid Pain Drug Product and Solutions
Table 15. Kenvue Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Kenvue Recent Developments and Future Plans
Table 17. Haleon Company Information, Head Office, and Major Competitors
Table 18. Haleon Major Business
Table 19. Haleon Non-Opioid Pain Drug Product and Solutions
Table 20. Haleon Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Bayer Company Information, Head Office, and Major Competitors
Table 22. Bayer Major Business
Table 23. Bayer Non-Opioid Pain Drug Product and Solutions
Table 24. Bayer Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 25. Bayer Recent Developments and Future Plans
Table 26. Pfizer Company Information, Head Office, and Major Competitors
Table 27. Pfizer Major Business
Table 28. Pfizer Non-Opioid Pain Drug Product and Solutions
Table 29. Pfizer Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Pfizer Recent Developments and Future Plans
Table 31. Pacira BioSciences Company Information, Head Office, and Major Competitors
Table 32. Pacira BioSciences Major Business
Table 33. Pacira BioSciences Non-Opioid Pain Drug Product and Solutions
Table 34. Pacira BioSciences Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Pacira BioSciences Recent Developments and Future Plans
Table 36. Heron Therapeutics Company Information, Head Office, and Major Competitors
Table 37. Heron Therapeutics Major Business
Table 38. Heron Therapeutics Non-Opioid Pain Drug Product and Solutions
Table 39. Heron Therapeutics Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Heron Therapeutics Recent Developments and Future Plans
Table 41. Scilex Holding Company Information, Head Office, and Major Competitors
Table 42. Scilex Holding Major Business
Table 43. Scilex Holding Non-Opioid Pain Drug Product and Solutions
Table 44. Scilex Holding Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Scilex Holding Recent Developments and Future Plans
Table 46. Grünenthal Company Information, Head Office, and Major Competitors
Table 47. Grünenthal Major Business
Table 48. Grünenthal Non-Opioid Pain Drug Product and Solutions
Table 49. Grünenthal Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Grünenthal Recent Developments and Future Plans
Table 51. Hisamitsu Pharmaceutical Company Information, Head Office, and Major Competitors
Table 52. Hisamitsu Pharmaceutical Major Business
Table 53. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product and Solutions
Table 54. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 55. Hisamitsu Pharmaceutical Recent Developments and Future Plans
Table 56. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 57. Daiichi Sankyo Major Business
Table 58. Daiichi Sankyo Non-Opioid Pain Drug Product and Solutions
Table 59. Daiichi Sankyo Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Daiichi Sankyo Recent Developments and Future Plans
Table 61. AFT Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 62. AFT Pharmaceuticals Major Business
Table 63. AFT Pharmaceuticals Non-Opioid Pain Drug Product and Solutions
Table 64. AFT Pharmaceuticals Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. AFT Pharmaceuticals Recent Developments and Future Plans
Table 66. Viatris Company Information, Head Office, and Major Competitors
Table 67. Viatris Major Business
Table 68. Viatris Non-Opioid Pain Drug Product and Solutions
Table 69. Viatris Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Viatris Recent Developments and Future Plans
Table 71. Teva Pharmaceutical Company Information, Head Office, and Major Competitors
Table 72. Teva Pharmaceutical Major Business
Table 73. Teva Pharmaceutical Non-Opioid Pain Drug Product and Solutions
Table 74. Teva Pharmaceutical Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Teva Pharmaceutical Recent Developments and Future Plans
Table 76. Dr. Reddy's Company Information, Head Office, and Major Competitors
Table 77. Dr. Reddy's Major Business
Table 78. Dr. Reddy's Non-Opioid Pain Drug Product and Solutions
Table 79. Dr. Reddy's Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Dr. Reddy's Recent Developments and Future Plans
Table 81. Sun Pharmaceutical Company Information, Head Office, and Major Competitors
Table 82. Sun Pharmaceutical Major Business
Table 83. Sun Pharmaceutical Non-Opioid Pain Drug Product and Solutions
Table 84. Sun Pharmaceutical Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 85. Sun Pharmaceutical Recent Developments and Future Plans
Table 86. Jiangsu Hengrui Company Information, Head Office, and Major Competitors
Table 87. Jiangsu Hengrui Major Business
Table 88. Jiangsu Hengrui Non-Opioid Pain Drug Product and Solutions
Table 89. Jiangsu Hengrui Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Jiangsu Hengrui Recent Developments and Future Plans
Table 91. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 92. Johnson & Johnson Major Business
Table 93. Johnson & Johnson Non-Opioid Pain Drug Product and Solutions
Table 94. Johnson & Johnson Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. Johnson & Johnson Recent Developments and Future Plans
Table 96. Hubei Hendi Pharmaceutical Company Information, Head Office, and Major Competitors
Table 97. Hubei Hendi Pharmaceutical Major Business
Table 98. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product and Solutions
Table 99. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. Hubei Hendi Pharmaceutical Recent Developments and Future Plans
Table 101. CSPC Pharmaceutical Group Company Information, Head Office, and Major Competitors
Table 102. CSPC Pharmaceutical Group Major Business
Table 103. CSPC Pharmaceutical Group Non-Opioid Pain Drug Product and Solutions
Table 104. CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. CSPC Pharmaceutical Group Recent Developments and Future Plans
Table 106. Simcere Pharmaceutical Company Information, Head Office, and Major Competitors
Table 107. Simcere Pharmaceutical Major Business
Table 108. Simcere Pharmaceutical Non-Opioid Pain Drug Product and Solutions
Table 109. Simcere Pharmaceutical Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Simcere Pharmaceutical Recent Developments and Future Plans
Table 111. Qilu Pharmaceutical Company Information, Head Office, and Major Competitors
Table 112. Qilu Pharmaceutical Major Business
Table 113. Qilu Pharmaceutical Non-Opioid Pain Drug Product and Solutions

+357 96 030922
info@marketpublishers.com

Table 114. Qilu Pharmaceutical Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Qilu Pharmaceutical Recent Developments and Future Plans
Table 116. Yichang Humanwell Pharmaceutical Company Information, Head Office, and Major Competitors
Table 117. Yichang Humanwell Pharmaceutical Major Business
Table 118. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product and Solutions
Table 119. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 120. Yichang Humanwell Pharmaceutical Recent Developments and Future Plans
Table 121. Tongfang Pharma Company Information, Head Office, and Major Competitors
Table 122. Tongfang Pharma Major Business
Table 123. Tongfang Pharma Non-Opioid Pain Drug Product and Solutions
Table 124. Tongfang Pharma Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 125. Tongfang Pharma Recent Developments and Future Plans
Table 126. Fresenius Company Information, Head Office, and Major Competitors
Table 127. Fresenius Major Business
Table 128. Fresenius Non-Opioid Pain Drug Product and Solutions
Table 129. Fresenius Non-Opioid Pain Drug Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 130. Fresenius Recent Developments and Future Plans
Table 131. Global Non-Opioid Pain Drug Revenue (USD Million) by Players (2021-2026)
Table 132. Global Non-Opioid Pain Drug Revenue Share by Players (2021-2026)
Table 133. Breakdown of Non-Opioid Pain Drug by Company Type (Tier 1, Tier 2, and Tier 3)
Table 134. Market Position of Players in Non-Opioid Pain Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 135. Head Office of Key Non-Opioid Pain Drug Players
Table 136. Non-Opioid Pain Drug Market: Company Product Type Footprint
Table 137. Non-Opioid Pain Drug Market: Company Product Application Footprint
Table 138. Non-Opioid Pain Drug New Market Entrants and Barriers to Market Entry
Table 139. Non-Opioid Pain Drug Mergers, Acquisition, Agreements, and Collaborations
Table 140. Global Non-Opioid Pain Drug Consumption Value (USD Million) by Type (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 141. Global Non-Opioid Pain Drug Consumption Value Share by Type (2021-2026)
Table 142. Global Non-Opioid Pain Drug Consumption Value Forecast by Type (2027-2032)
Table 143. Global Non-Opioid Pain Drug Consumption Value by Application (2021-2026)
Table 144. Global Non-Opioid Pain Drug Consumption Value Forecast by Application (2027-2032)
Table 145. North America Non-Opioid Pain Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 146. North America Non-Opioid Pain Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 147. North America Non-Opioid Pain Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 148. North America Non-Opioid Pain Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 149. North America Non-Opioid Pain Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 150. North America Non-Opioid Pain Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 151. Europe Non-Opioid Pain Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 152. Europe Non-Opioid Pain Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 153. Europe Non-Opioid Pain Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 154. Europe Non-Opioid Pain Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 155. Europe Non-Opioid Pain Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 156. Europe Non-Opioid Pain Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 157. Asia-Pacific Non-Opioid Pain Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 158. Asia-Pacific Non-Opioid Pain Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 159. Asia-Pacific Non-Opioid Pain Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 160. Asia-Pacific Non-Opioid Pain Drug Consumption Value by Application

+357 96 030922
info@marketpublishers.com

(2027-2032) & (USD Million)
Table 161. Asia-Pacific Non-Opioid Pain Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 162. Asia-Pacific Non-Opioid Pain Drug Consumption Value by Region (2027-2032) & (USD Million)
Table 163. South America Non-Opioid Pain Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 164. South America Non-Opioid Pain Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 165. South America Non-Opioid Pain Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 166. South America Non-Opioid Pain Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 167. South America Non-Opioid Pain Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 168. South America Non-Opioid Pain Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 169. Middle East & Africa Non-Opioid Pain Drug Consumption Value by Type (2021-2026) & (USD Million)
Table 170. Middle East & Africa Non-Opioid Pain Drug Consumption Value by Type (2027-2032) & (USD Million)
Table 171. Middle East & Africa Non-Opioid Pain Drug Consumption Value by Application (2021-2026) & (USD Million)
Table 172. Middle East & Africa Non-Opioid Pain Drug Consumption Value by Application (2027-2032) & (USD Million)
Table 173. Middle East & Africa Non-Opioid Pain Drug Consumption Value by Country (2021-2026) & (USD Million)
Table 174. Middle East & Africa Non-Opioid Pain Drug Consumption Value by Country (2027-2032) & (USD Million)
Table 175. Global Key Players of Non-Opioid Pain Drug Upstream (Raw Materials)
Table 176. Global Non-Opioid Pain Drug Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Non-Opioid Pain Drug Picture
Figure 2. Global Non-Opioid Pain Drug Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Non-Opioid Pain Drug Consumption Value Market Share by Type in 2025
Figure 4. Acetaminophen/Paracetamol
Figure 5. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Figure 6. Selective COX-2 Inhibitors
Figure 7. Sodium Channel Pain Signal Inhibitors
Figure 8. Local Anesthetic Analgesics
Figure 9. Other
Figure 10. Global Non-Opioid Pain Drug Consumption Value by Drug Ingredients, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Non-Opioid Pain Drug Consumption Value Market Share by Drug Ingredients in 2025
Figure 12. Single-Agent Drugs
Figure 13. Combination Drugs
Figure 14. Global Non-Opioid Pain Drug Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Non-Opioid Pain Drug Consumption Value Market Share by Route of Administration in 2025
Figure 16. Oral Drugs
Figure 17. Injectable Drugs
Figure 18. Topical Drugs
Figure 19. Global Non-Opioid Pain Drug Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 20. Non-Opioid Pain Drug Consumption Value Market Share by Application in 2025
Figure 21. Postoperative Pain Picture
Figure 22. Musculoskeletal Pain Picture
Figure 23. Arthritis Pain Picture
Figure 24. Neuropathic Pain Picture
Figure 25. Headache and Migraine Picture
Figure 26. Other Picture
Figure 27. Global Non-Opioid Pain Drug Consumption Value, (USD Million): 2021 &

+357 96 030922
info@marketpublishers.com

2025 & 2032
Figure 28. Global Non-Opioid Pain Drug Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 29. Global Market Non-Opioid Pain Drug Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 30. Global Non-Opioid Pain Drug Consumption Value Market Share by Region (2021-2032)
Figure 31. Global Non-Opioid Pain Drug Consumption Value Market Share by Region in 2025
Figure 32. North America Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 33. Europe Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 34. Asia-Pacific Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 35. South America Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 36. Middle East & Africa Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 37. Company Three Recent Developments and Future Plans
Figure 38. Global Non-Opioid Pain Drug Revenue Share by Players in 2025
Figure 39. Non-Opioid Pain Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 40. Market Share of Non-Opioid Pain Drug by Player Revenue in 2025
Figure 41. Top 3 Non-Opioid Pain Drug Players Market Share in 2025
Figure 42. Top 6 Non-Opioid Pain Drug Players Market Share in 2025
Figure 43. Global Non-Opioid Pain Drug Consumption Value Share by Type (2021-2026)
Figure 44. Global Non-Opioid Pain Drug Market Share Forecast by Type (2027-2032)
Figure 45. Global Non-Opioid Pain Drug Consumption Value Share by Application (2021-2026)
Figure 46. Global Non-Opioid Pain Drug Market Share Forecast by Application (2027-2032)
Figure 47. North America Non-Opioid Pain Drug Consumption Value Market Share by Type (2021-2032)
Figure 48. North America Non-Opioid Pain Drug Consumption Value Market Share by Application (2021-2032)
Figure 49. North America Non-Opioid Pain Drug Consumption Value Market Share by Country (2021-2032)

+357 96 030922
info@marketpublishers.com

Figure 50. United States Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 51. Canada Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 52. Mexico Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 53. Europe Non-Opioid Pain Drug Consumption Value Market Share by Type (2021-2032)
Figure 54. Europe Non-Opioid Pain Drug Consumption Value Market Share by Application (2021-2032)
Figure 55. Europe Non-Opioid Pain Drug Consumption Value Market Share by Country (2021-2032)
Figure 56. Germany Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 57. France Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 58. United Kingdom Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 59. Russia Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 60. Italy Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 61. Asia-Pacific Non-Opioid Pain Drug Consumption Value Market Share by Type (2021-2032)
Figure 62. Asia-Pacific Non-Opioid Pain Drug Consumption Value Market Share by Application (2021-2032)
Figure 63. Asia-Pacific Non-Opioid Pain Drug Consumption Value Market Share by Region (2021-2032)
Figure 64. China Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 65. Japan Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 66. South Korea Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 67. India Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 68. Southeast Asia Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 69. Australia Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 70. South America Non-Opioid Pain Drug Consumption Value Market Share by

+357 96 030922
info@marketpublishers.com

Type (2021-2032)
Figure 71. South America Non-Opioid Pain Drug Consumption Value Market Share by Application (2021-2032)
Figure 72. South America Non-Opioid Pain Drug Consumption Value Market Share by Country (2021-2032)
Figure 73. Brazil Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 74. Argentina Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 75. Middle East & Africa Non-Opioid Pain Drug Consumption Value Market Share by Type (2021-2032)
Figure 76. Middle East & Africa Non-Opioid Pain Drug Consumption Value Market Share by Application (2021-2032)
Figure 77. Middle East & Africa Non-Opioid Pain Drug Consumption Value Market Share by Country (2021-2032)
Figure 78. Turkey Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 79. Saudi Arabia Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 80. UAE Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 81. Non-Opioid Pain Drug Market Drivers
Figure 82. Non-Opioid Pain Drug Market Restraints
Figure 83. Non-Opioid Pain Drug Market Trends
Figure 84. Porters Five Forces Analysis
Figure 85. Non-Opioid Pain Drug Industrial Chain
Figure 86. Methodology
Figure 87. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Non-Opioid Pain Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: https://marketpublishers.com/r/GB845ED2F715EN.html

Price: US$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GB845ED2F715EN.html